Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial Infarction
Status:
Completed
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
Taken together the results from DAPT and PEGASUS-TIMI54, it appears that physicians may
consider extending beyond 1 year or reinitiating treatment with a thienopyridine or
ticagrelor 60mg bid in patients with a prior MI and features of high ischemic and low
bleeding risk. Comparative clinical or pharmacodynamic studies, however, between prasugrel 5
mg od and ticagrelor 60 mg bid in the chronic phase of stable post MI patients have not been
performed.
In light of this, we believe that a dedicated pharmacodynamic study of ticagrelor 60 bid mg
vs prasugrel 5 mg od in a PEGASUS-like population would be informative for the practicing
clinician, thus setting the rationale for conducting this specifically designed
investigation.